The US FDA's accelerated approval of Bristol-Myers Squibb Co.'s PD-1 inhibitor Opdivo for second-line hepatocellular carcinoma paves a path for checkpoint immunotherapies in yet another traditionally underserved tumor type.
FDA announced the new approval of Opdivo Sept. 22 for use after Bayer AG's oral, kinase inhibitor mainstay Nexavar...






